Kolon TissueGene will receive additional funds through a capital increase to be participated in by the Kolon Group and its Chairman Lee Woong-yeol.According to TissueGene, the company issued a capital increase of about 38.8 billion won ($29.6 million) last Friday. The number of shares issued followi
Voronoi said Friday that its next-generation non-small cell lung cancer (NSCLC) drug candidate, VRN11, has been selected as a new non-clinical support project by the Korea Drug Development Fund (KDDF).Voronoi will receive 1.2 billion won ($920,000) in full-time research and development expenses for
Menarini’s elacestrant, an oral selective estrogen receptor downregulator (SERD), is expected to obtain U.S. FDA approval in February, initiating competition against fulvestrant (brand name: Faslodex), a leading blockbuster drug in the breast cancer treatment market.On Thursday, the FDA announced th
Ilias Biologics said Thursday that its project to research and develop a treatment for inflammatory bowel disease (IBD) has been selected as the second national drug development project this year.The company added that it has also signed a final agreement.The national drug development project is an
Hanall Biopharma, a subsidiary of Daewoong Pharmaceutical, said it expanded the lineup of Biotop, over-the-counter probiotics.On Wednesday, Hanall Biopharma said it released Biotop Forte Cap. and Biotop Dual Cap.The existing Biotop series include Biotop D, a combination of lactic acid, butyric acid,
Biogen dropped its plan to roll out Alzheimer’s disease treatment Aduhelm (ingredient: aducanumab) in Korea, sources said.The company reportedly told the Ministry of Food and Drug Safety that it would withdraw its application for Aduhelm approval.Earlier, the Central Pharmaceutical Affairs Council m
Ahead of the influenza season, Kwangdong Pharmaceutical said on Wednesday that it would start selling GSK’s quadrivalent flu vaccine, Fluarix Tetra, in Korea.Kwangdong has been handling the local distribution of Fluarix Tetra since last year. This year, the company plans to expand the vaccine distri
Icure Pharmaceutical, a company specializing in drug delivery systems, has set about to expand oral incrementally modified drug (IMD) pipelines.The company said Wednesday that it had signed a technology transfer agreement with Hanall Biopharma on IMD for gastroesophageal reflux disease (GERD). Under
Eyegene said on Tuesday that it signed an agreement to develop a Japanese encephalitis virus gene-recombinant vaccine with financial support from the Korea Health Industry Development Institute (KHIDI).The research and development cost is estimated to be 200 million won ($150,000), and the state age
Idience said Tuesday that venadaparib, the company’s novel drug candidate for targeted agents, has been designated as an orphan drug by the U.S. Food and Drug Administration.Idience is a subsidiary of Ildong Holdings, the holding company of Ildong Pharmaceutical Group, specializing in novel drug dev
Hanmi Pharmaceutical said it was ready to lead the local dyslipidemia treatment market with Rosuzet (rosuvastatin 10mg+ezetimibe 10mg) because of the treatment’s “distinguished evidence for therapeutic benefits.”At a news conference in Seoul Monday, Hanmi disclosed the results of the RACING trial, s
Pharmaceutical experts repeatedly said SK Bioscience’s Covid-19 vaccine SKYCovione needed additional safety review during the regulator’s marketing approval process, minutes of a drug review panel showed.The Ministry of Food and Drug Safety recently disclosed the minutes of the Central Pharmaceutica
SK Biopharmaceuticals’ epilepsy drug Cenobamate will soon be reviewed for approval in Canada and Israel.Paladin Labs, a subsidiary of SK Biopharma’s partner company Endo International, sent new drug submission (NDS) for the innovative novel drug for epilepsy to Health Canada in June.If the Canadian
Genematrix said Monday that it obtained the Conformité Européene In-vitro diagnostic (CE-IVD) device certification for its new Neoflex TB/NTM-5 detection kit, a new respiratory diagnostic product.The kit can identify one type of mycobacterium tuberculosis (TB) and five different types of non-tubercu
Pangen Biotech announced Monday that it signed a joint development agreement with Moogene Medi to develop a protein treatment using lipid nanoparticles (LNPs).The two companies also applied for a patent on “LNPs for protein transfer” in July.LNPs are transmitter substances of mRNA Covid-19 vaccine d
MedPacto announced Monday that it received green light from the U.S. FDA to test Vactosertib as a solo therapy for recurrent and intractable osteosarcoma patients in a phase 1/2 trial.The study will be on 54 patients aged 14 or older who suffer from recurrent or intractable osteosarcoma and carried
Cellid, a Korean bio-venture, will conduct a Covid-19 vaccine study in Kenya and Tanzania, a company official said.“In the near future, we will apply for an investigational new drug (IND) clinical trial in Kenya and Tanzania, jointly with the International Vaccine Institute (IVI),” the official told
Novo Nordisk is facing difficulties to replace the existing drug Saxenda (liraglutide) with a new drug Wegovy (semaglutide) in the obesity treatment market due to manufacturing issues.On Thursday, the Danish multinational drugmaker said in an IR meeting for second-quarter earnings that it would be d
Macrogen, a company specializing in precision medicine biotechnology, said on Monday that it is expanding its multiomics business by providing domestic and foreign protein analysis services.Multiomics is a high-level analytical technique that integrates genomic, transcriptome, and proteome data, and
Bukwang Pharmaceutical its subsidiary Dyna Therapeutics obtained a composition patent for SOL-804, a prostate cancer drug candidate, in Korea and Japan.With the additional two patent registrations, Dyna has completed the patent registration in 32 countries including the U.S., Australia, Mexico, and